[1. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al.; American Heart Association; American Stroke Association. Update to the AHA/ ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008; 39(5): 1647-1652.10.1161/STROKEAHA.107.189063419833518322260]Search in Google Scholar
[2. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg. 2011; 76(6 Suppl): S85-S90.10.1016/j.wneu.2011.07.02322182277]Search in Google Scholar
[3. Tousoulis D, Siasos G, Zaromitidou M, Oikonomou E, Maniatis K, Kioufis S, et al. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel. Int J Cardiol. 2013; 168(2): 1594-1596.10.1016/j.ijcard.2013.01.04023402725]Search in Google Scholar
[4. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2006; 26(7): 1648-165210.1161/01.ATV.0000225288.74170.dc16675725]Search in Google Scholar
[5. Chae H, Kim M, Koh YS, Hwang BH, Kang MK, Kim Y, et al. Feasibility of a microarraybased point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. Biomed Res Int. 2013; 2013: 154073. doi: 10.1155/2013/154073.10.1155/2013/154073362560523607088]Search in Google Scholar
[6. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Gene: CYP2C19. Available from: http://www.pharmgkb.org/gene/PA124. Accessed November 10 2014.]Search in Google Scholar
[7. Scott SA, Sangkuhl K, Gardner EE, Stein CM. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Parmacol Therapeut. 2011; 90(2): 328-332.10.1038/clpt.2011.132323430121716271]Search in Google Scholar
[8. Kaikita K, Ono T, Iwashita S, Nakayama N, Sato K, Horio E, et al. Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb. 2014; 21(1): 64-76.10.5551/jat.1895224088578]Search in Google Scholar
[9. Kim KA, Song WG, Lee HM, Joo HJ, Park JY. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population. Thromb Res. 2013; 132(2): 221-226.10.1016/j.thromres.2013.06.02023849096]Search in Google Scholar
[10. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84(5): 891-896.10.1055/s-0037-1614133]Search in Google Scholar
[11. Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2methylthio ADP to rat platelets - Effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 1994; 269(2): 772-777.]Search in Google Scholar
[12. Feng D, Lindpaintner K, Larson MG, Rao VS, O’Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1999; 19(4): 1142-1147.10.1161/01.ATV.19.4.1142]Search in Google Scholar
[13. Lordkipanidze M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C. Genetic determinants of response to aspirin: Appraisal of 4 candidate genes. Thromb Res. 2011; 128(1): 47-5310.1016/j.thromres.2011.02.019]Search in Google Scholar
[14. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke. 2005; 36(7): 1394-1399.10.1161/01.STR.0000169922.79281.a5]Search in Google Scholar
[15. Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis. 2013; 106(10): 517-527.10.1016/j.acvd.2013.06.055]Search in Google Scholar
[16. Tang XF, Zhang JH, Wang J, Han YL, Xu B, Qiao SB, et al. Effects of coexisting polymorphisms of CYP2 C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl). 2013; 126(6): 1069-1075.]Search in Google Scholar
[17. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE). Lancet. 1996; 348 (9038): 1329-1339.10.1016/S0140-6736(96)09457-3]Search in Google Scholar
[18. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003; 91(9): 1123-1125.10.1016/S0002-9149(03)00163-2]Search in Google Scholar
[19. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107(23): 2908-2913.10.1161/01.CIR.0000072771.11429.8312796140]Search in Google Scholar
[20. Spokoyny I, Barazangi N, Jaramillo V, Rose J, Chen C, Wong C, et al. Reduced clopidogrel metabolism in a multiethnic population: Prevalence and rates of recurrent cerebrovascular events. J Stroke Cerebrovasc Dis. 2014; 23(4): 694-698.10.1016/j.jstrokecerebrovasdis.2013.06.00823849748]Search in Google Scholar
[21. Anderson CD, Biffi A, Greenberg SM, Rosand J. Personalized approaches to clopidogrel therapy: Are we there yet? Stroke. 2010; 41(12): 2997-3002.10.1161/STROKEAHA.110.594069301468321030701]Search in Google Scholar
[22. US Food and Drug Administration. Clopidogrel black box warning. Available from: http:// www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm203888.htm. Accessed November 10, 2014.]Search in Google Scholar
[23. Terpening C. Clopidogrel: A pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol. 2010; 4(1): 117-128. 10.4137/CMC.S4323299893521151850]Search in Google Scholar